Synergistic Anti-Tumor Effects of Sulfatinib and Kaempferol on Pancreatic Neuroendocrine Tumors via CALCA-mediated PI3K/AKT/mTOR Pathway
Lingyi Chen, Pengfei Liu, Fengjuan Chen, Bingyan Xue, Xu Han, Lijun Yan, Jianan Bai, Xiaoya Li, Min Liu, Ye Tian, Mujie Ye, Qiyun Tang
TL;DR
Combining sulfatinib and kaempferol shows promise in treating pancreatic neuroendocrine tumors by inhibiting tumor growth and angiogenesis.
Contribution
The study identifies a synergistic anti-tumor effect of sulfatinib and kaempferol via CALCA-mediated modulation of the PI3K/AKT/mTOR pathway.
Findings
The combination of sulfatinib and low-dose kaempferol enhances sensitivity of pNET cells to sulfatinib.
The combination synergistically inhibits angiogenesis in both in vitro and in vivo models.
Transcriptome sequencing identified CALCA as a key molecule in the anti-tumor synergy.
Abstract
Pancreatic neuroendocrine tumors (pNETs) represent a diverse category of neoplasms originating from pancreatic neuroendocrine cells. Although these tumors generally exhibit a relatively indolent nature, they often metastasize early in their course, significantly affecting patient outcomes. Sulfatinib (SULF) is associated with considerable toxicity and resistance challenges, leading to many patients failing to achieve long-term disease management. In contrast, Kaempferol (KMP), a naturally occurring phytochemical, has shown considerable promise in anti-tumor treatments. Our study revealed that the combination of SULF and low-dose KMP enhances the sensitivity of pNET cells to SULF. Moreover, this combination demonstrated a synergistic effect on angiogenesis inhibition, observed in both in vitro and in vivo environments. Additionally, we confirmed this synergistic anti-tumor effect using a…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNeuroendocrine Tumor Research Advances · Pancreatic and Hepatic Oncology Research · PI3K/AKT/mTOR signaling in cancer